Moderna stock tumbled after the Senate Finance Committee voted to send RFK Jr.'s nomination for the HHS secretary to the full ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be revisiting its all-time highs for revenue or earnings in the next three years.

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

Since then, though, Moderna has traveled along a rough path. Demand for the coronavirus vaccine has dropped significantly, and even the company's second approved product -- respiratory syncytial ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna is focused on treating rare diseases in this modality and has two programs with early promising data that are entering pivotal development in 2024 (we assign probabilities of approval of 50%).

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the next three years, and reducing costs across our business." MRNA Stock Is in a ...

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot — its second approved product — has been slower than expected, forcing Moderna to cut costs.

Moderna enters 2025 with a focus on a prioritized ... "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and continued to adapt our COVID-19 business for ...